Glenview Trust Co Acquires 15,559 Shares of Humana Inc. $HUM

Glenview Trust Co lifted its holdings in Humana Inc. (NYSE:HUM) by 40.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,692 shares of the insurance provider’s stock after acquiring an additional 15,559 shares during the period. Glenview Trust Co’s holdings in Humana were worth $13,752,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Sound View Wealth Advisors Group LLC lifted its holdings in shares of Humana by 3.5% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider’s stock valued at $272,000 after acquiring an additional 36 shares during the last quarter. Unison Advisors LLC raised its position in Humana by 0.4% in the 3rd quarter. Unison Advisors LLC now owns 10,137 shares of the insurance provider’s stock worth $2,646,000 after purchasing an additional 37 shares during the period. CoreCap Advisors LLC raised its position in Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares during the period. Insigneo Advisory Services LLC raised its position in Humana by 3.0% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock worth $386,000 after purchasing an additional 43 shares during the period. Finally, Columbus Macro LLC raised its position in Humana by 5.5% in the 4th quarter. Columbus Macro LLC now owns 821 shares of the insurance provider’s stock worth $210,000 after purchasing an additional 43 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of HUM stock opened at $307.79 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. The company has a market capitalization of $36.95 billion, a P/E ratio of 32.92, a P/E/G ratio of 2.86 and a beta of 0.68. The company’s 50-day simple moving average is $218.13 and its two-hundred day simple moving average is $227.27. Humana Inc. has a one year low of $163.11 and a one year high of $315.66.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 EPS for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. The business had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. The company’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, equities analysts anticipate that Humana Inc. will post 9.01 EPS for the current year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Friday, June 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.2%. The ex-dividend date is Friday, June 26th. Humana’s dividend payout ratio is currently 37.86%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on HUM shares. UBS Group increased their price objective on shares of Humana from $262.00 to $320.00 and gave the stock a “neutral” rating in a research report on Friday. The Goldman Sachs Group increased their price objective on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a research report on Thursday, April 30th. Seaport Research Partners lowered shares of Humana to a “neutral” rating in a research report on Wednesday. Needham & Company LLC started coverage on shares of Humana in a research report on Wednesday. They issued a “buy” rating on the stock. Finally, JPMorgan Chase & Co. increased their price objective on shares of Humana from $180.00 to $214.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Nine investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $263.35.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.